7Baggers
 Arvinas (NASDAQ:ARVN) Trading 8% Higher - Here's Why  MarketBeat Sun, 16 Nov 2025 19:31:41 GMT
 Published on: 2025-11-15 14:53:07  newser.com Sat, 15 Nov 2025 20:53:07 GMT
 Published on: 2025-11-15 03:36:12  newser.com Sat, 15 Nov 2025 09:36:12 GMT
 Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Stephens  MarketBeat Tue, 11 Nov 2025 14:39:47 GMT
 Stephens raises Arvinas stock price target to $15 on program updates  Investing.com Nigeria Tue, 11 Nov 2025 06:55:26 GMT
 stephens & co. raises arvinas (arvn) price target to $15.00 | ar  GuruFocus Mon, 10 Nov 2025 14:45:03 GMT
 arvinas price target raised to $15 from $14 at stephens  TipRanks Mon, 10 Nov 2025 12:55:39 GMT
 stephens raises arvinas stock price target to $15 on program updates  Investing.com Mon, 10 Nov 2025 12:36:08 GMT
 Arvinas, Inc. $ARVN Shares Acquired by Monaco Asset Management SAM  MarketBeat Mon, 10 Nov 2025 12:12:42 GMT
 Wedbush Has Bullish Estimate for Arvinas FY2025 Earnings  MarketBeat Mon, 10 Nov 2025 07:55:43 GMT
 fy2025 eps estimates for arvinas raised by leerink partnrs  MarketBeat Mon, 10 Nov 2025 07:55:43 GMT
 Cantor Fitzgerald Boosts Earnings Estimates for Arvinas  MarketBeat Mon, 10 Nov 2025 07:55:42 GMT
 HC Wainwright Analysts Lift Earnings Estimates for Arvinas  MarketBeat Mon, 10 Nov 2025 07:55:42 GMT
 published on: 2025-11-09 12:06:09  newser.com Sun, 09 Nov 2025 18:06:09 GMT
 What is HC Wainwright's Forecast for Arvinas Q1 Earnings?  MarketBeat Sat, 08 Nov 2025 15:48:00 GMT
 What is Wedbush's Estimate for Arvinas Q1 Earnings?  MarketBeat Sat, 08 Nov 2025 08:00:00 GMT
 John Houston Stepping Down as Arvinas CEO  CBIA Fri, 07 Nov 2025 08:00:00 GMT
 Arvinas (NASDAQ:ARVN) Price Target Raised to $16.00  MarketBeat Fri, 07 Nov 2025 08:00:00 GMT
 wedbush reaffirms neutral rating for arvinas (nasdaq:arvn)  MarketBeat Fri, 07 Nov 2025 08:00:00 GMT
 arvinas (arvn): wells fargo lowers price target to $15 | arvn st  GuruFocus Fri, 07 Nov 2025 05:50:37 GMT
 arvinas (arvn): wells fargo lowers price target to $15 | arvn st  GuruFocus Thu, 06 Nov 2025 16:43:15 GMT
 arvinas, inc. (nasdaq:arvn) q3 2025 earnings call transcript  Insider Monkey Thu, 06 Nov 2025 14:23:28 GMT
 oppenheimer maintains arvinas(arvn.us) with hold rating  富途牛牛 Thu, 06 Nov 2025 05:31:00 GMT
 arvinas reports q3 2025 earnings and strategic progress  TipRanks Thu, 06 Nov 2025 05:29:59 GMT
 arvinas, inc. (arvn) reports q3 loss, tops revenue estimates  sharewise.com Thu, 06 Nov 2025 03:12:30 GMT
 arvinas inc (arvn) q3 2025 earnings call highlights: clinical ad  GuruFocus Thu, 06 Nov 2025 02:56:11 GMT
 arvinas reports q3 eps (48c), consensus (74c)  TipRanks Wed, 05 Nov 2025 20:27:40 GMT
 arvinas shrinks losses as wall street sees more upside  Finimize Wed, 05 Nov 2025 15:01:17 GMT
 arvinas sees cash runway into 2h28  TipRanks Wed, 05 Nov 2025 14:24:22 GMT
 arvinas (arvn) exceeds q3 revenue expectations with strategic gr  GuruFocus Wed, 05 Nov 2025 12:44:39 GMT
 Biotech firm Arvinas' Q3 net loss narrows  TradingView Wed, 05 Nov 2025 12:19:29 GMT
 Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance Wed, 05 Nov 2025 08:00:00 GMT
 Arvinas earnings beat by $0.23, revenue topped estimates  Investing.com Wed, 05 Nov 2025 08:00:00 GMT
 avoiding lag: real-time signals in (arvn) movement  news.stocktradersdaily.com Tue, 04 Nov 2025 18:16:03 GMT
 bayer-backed firm shutters after failed funding round  The Business Journals Tue, 04 Nov 2025 12:37:00 GMT
 Earnings To Watch: Arvinas Inc (ARVN) Reports Q3 2025 Result  Yahoo Finance Tue, 04 Nov 2025 08:00:00 GMT
 arvinas to present data on bcl6 degrader at ash annual meeting  Investing.com Nigeria Tue, 04 Nov 2025 04:04:20 GMT
 Arvinas to Participate in Upcoming Investor Conferences  GlobeNewswire Mon, 03 Nov 2025 12:00:00 GMT
 Arvinas to present data on BCL6 degrader at ASH annual meeting  Investing.com Mon, 03 Nov 2025 08:00:00 GMT

Arvinas, Inc
(NASDAQ:ARVN) 

ARVN stock logo

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical tri...

Founded: 2013
Full Time Employees: 133
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends